Selenium as a Potential Treatment for Moderately-ill, Severely-ill, and Critically-ill COVID-19 Patients.
Status:
Not yet recruiting
Trial end date:
2021-12-15
Target enrollment:
Participant gender:
Summary
Given its anti-viral, anti-oxidative, immune-enhancing, cytokine-modulating, and
anticoagulant properties, the investigators hypothesize that Selenium infusion at
supranutritional doses for moderately-ill, severely-ill, and critically-ill COVID-19 patients
will prevent further clinical deterioration thus decreasing overall mortality and improving
survival. To test this hypothesis, a prospective, single-center, phase II trial is proposed
to assess the efficacy of Selenium in hospitalized adult patients with moderate, severe, and
critical COVID-19 infections.